J&J says its single dose protects against breakthrough COVID-19 for up to 6 months

Written by Medical Dialogues Bureau Published On 2022-01-10T14:30:34+05:30 | Updated On 10 Jan 2022 2:30 PM IST

J&J says its single dose protects against breakthrough COVID-19 for up to 6 months

Listen to this Article

Johnson & Johnson (JNJ.N) said on Thursday that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.

The study, sponsored by the vaccine developer, was conducted between Jan. 1 and Sept. 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.

Also Read:Johnson and Johnson to split into 2 companies

J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc (PFE.N) and BioNTech's (22UAy.DE) as well as Moderna (MRNA.O).

No waning of protection was found for ICU admissions for all the three vaccines, J&J said.

The company said the study was carried out by collecting claims and laboratory data covering 168 million people.

Also Read:JnJ gets CDSCO panel nod for COVID vaccine study in 12-17 year old

Johnson & JohnsonJ&JJohnson & Johnson newscovidcovid 19ModernaModerna news

Source : Reuters

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.